Mabgeek Biotech has successfully completed its Series B financing, facilitating innovation in the biopharmaceutical industry.
2024-08-12 0
Recently, Hunan Mabgeek Biotech Co., Ltd. (hereinafter referred to as " Mabgeek Biotech "), a leading domestic innovative antibody drug research and development company, announced the successful completion of its B round of financing, with a financing amount of over RMB 200 million. This financing not only It demonstrates Mabgeek Biotech 's strong strength and broad prospects in the field of antibody drug research and development, and is also a solid step taken by the company in promoting the high-quality development of the biopharmaceutical industry.
where MG-K10, a star drug under development, as a monoclonal antibody targeting IL-4Rα, has shown global best-in-class potential. On the one hand, MG-K10 has the property of extending the half-life, and is the only half-life extended anti-IL in the world that has entered the late clinical stage. -4Rα drugs can achieve twice the dosing interval of drugs with the same target; on the other hand, the target dose group consistently showed higher efficacy than the marketed drugs with the same target in multiple efficacy endpoints of the Phase II clinical trials of atopic dermatitis and asthma. therapeutic response. With outstanding clinical advantages, the drug is being developed in Europe and the United States simultaneously. In the field of atopic dermatitis, the top-line data of its Phase II clinical trial will be presented in oral presentations at Bio-Europe 2023 and in posters at the 2024 American Academy of Dermatology Annual Meeting. It has won wide acclaim from experts and scholars at home and abroad. MG-K10 has entered Phase III clinical trials for atopic dermatitis, and Phase III clinical trials for asthma are being initiated.
< span style="font-size: 15px;">
< /span>
Chairman of Mabgeek Biotech Zhang ChenghaiDoctorsaid: "We sincerely welcome the new shareholders to join us. Their strong support not only injects strong financial momentum into the company, but also brings valuable industry resources and strategic vision. Here, we also thank We would like to express our deepest gratitude to the old shareholders who have accompanied us in our growth and given us firm trust and support. The company's MG-K10 has unique advantages in the treatment of atopic dermatitis. Its long-term efficacy, significant efficacy and Its good safety and tolerability give it broad application prospects in the future market. The company will continue to focus on research and development and innovation in the field of allergy and autoimmunity, and continuously promote the transformation and application of scientific research results. ”
Tianrui Fengnian Founding Partner Zhou Chunling said: "Magigene's innovative achievements in the field of biotechnology are remarkable, and its team's professional capabilities and market insights have left a deep impression on us. We believe that through this With the financing, Mabgeek Biotech tech will be able to further accelerate the pace of product research and development and bring benefits to more patients. We look forward to working together with Mabgeek Biotech to jointly open a new chapter in biotechnology. ”
< img class="rich_pages wxw-img js_insertlocalimg" style="float: left; height: auto !important; visibility: visible !important; width: 645.333px !important;" src="http://www.mabge.com/uploadfile/202501/30945ef4674c4e5 .jpg" alt="image">Ouyang Xiangjiang, Chairman of Xiangjiang State Investment, said: "Magigen has made remarkable achievements in the field of allergies and autoimmunity with its profound scientific research foundation and efficient execution. We firmly believe that with the injection of funds, Magigen will It can accelerate the development of drugs under investigation and bring more benefits to patients around the world. We look forward to working with Mabgeek Biotech to create a brilliant future. ”
Looking to the future, Mabgeek Biotech will continue to adhere to the research and development concept of "innovation, efficiency and safety" and continue to increase The company plans to launch more innovative drugs with independent intellectual property rights in the next few years to bring safer, more effective and convenient treatment options to patients around the world. Actively cooperate with outstanding domestic and foreign companies, scientific research institutions and medical institutions to jointly promote the innovative development of the biopharmaceutical industry and contribute more to human health.